Related Experiment Video
Updated: Jul 30, 2025

Author Spotlight: Treating Knee Osteoarthritis with Tuina - A New Perspective
Published on: January 12, 2024
Towards disease modification in osteoarthritis
Francesco Dell'Accio1, Cosimo De Bari2
1William Harvey Research Institute, Queen Mary, University of London, UK.
None:
In December 2022, Gerwin et al published in Nature Medicine that the C-terminal portion of angiopoietin-like 3, called LNA043, has chondroprotective and cartilage-regenerative properties. Molecular data from an experimental medicine phase I study suggested potential efficacy in humans. Here, we respond to and complement a commentary from Vincent and Conaghan and discuss unresolved issues and the potential of this molecule as a disease-modifying osteoarthritis drug.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Atherosclerosis III: Management
Osteoclasts in Bone Remodeling
Rheumatic Heart Disease IV: Nursing Management
COPD: Management Using Bronchodilators and Corticosteroids
Atherosclerosis IV: Nursing Management

